{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:25:18Z","timestamp":1792448718891,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["742390"],"award-info":[{"award-number":["742390"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["213662"],"award-info":[{"award-number":["213662"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100026893","name":"Center for Advancing Research Impact in Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["493624887"],"award-info":[{"award-number":["493624887"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1136\/ard-2024-226051","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T13:20:11Z","timestamp":1730985611000},"page":"262-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways"],"prefix":"10.1016","volume":"84","author":[{"given":"Georgia-Savina","family":"Moysidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Garantziotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sentis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Nikoleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Malissovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Nikoloudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini-Maria","family":"Stergioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Polia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Paschalidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Filia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Grigoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysis","family":"Nikolopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemin","family":"Kapsala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Katechis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Fanouriakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios T.","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-226051_bib0001","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/art.40511","article-title":"Hypocomplementemic Patients With Systemic Lupus Erythematosus","volume":"70","author":"Doria","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226051_bib0002","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.semarthrit.2018.02.014","article-title":"Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study","volume":"48","author":"Fanouriakis","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2024-226051_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1759720X17690474","article-title":"Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness","volume":"9","author":"Guerreiro Castro","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2024-226051_bib0004","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12016-018-8675-2","article-title":"Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies","volume":"54","author":"Trentin","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1136\/ard-2024-226051_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000634","article-title":"Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria","volume":"9","author":"van Vollenhoven","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2024-226051_bib0006","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/art.40439","article-title":"Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226051_bib0007","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-226051_bib0008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.40861","article-title":"Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226051_bib0009","first-page":"699","article-title":"Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care","volume":"25","author":"Bruce","year":"2016","journal-title":"Lupus (Los Angel)"},{"key":"10.1136\/ard-2024-226051_bib0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/annrheumdis-2018-214043","article-title":"Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis","volume":"78","author":"Urowitz","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226051_bib0011","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2011.48","article-title":"Connective tissue diseases: targeting B cells in SLE: good news at last!","volume":"7","author":"Sanz","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-226051_bib0012","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2005-12-017319","article-title":"A role for BLyS in the activation of innate immune cells","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"10.1136\/ard-2024-226051_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000976","article-title":"High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus","volume":"10","author":"Maeda","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2024-226051_bib0014","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/ard-2023-224919","volume":"83","author":"Pitsigavdaki","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226051_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226051_bib0016","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226051_bib0017","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-020-02177-0","article-title":"The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis","volume":"22","author":"Wilkinson","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226051_bib0018","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-226051_bib0019","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226051_bib0020","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-226051_bib0021","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.1780340802","article-title":"Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study","volume":"34","author":"Petri","year":"1991","journal-title":"Arthritis & Rheum"},{"key":"10.1136\/ard-2024-226051_bib0022","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-226051_bib0023","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226051_bib0024","unstructured":"Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. Available: http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc"},{"key":"10.1136\/ard-2024-226051_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1136\/ard-2024-226051_bib0026","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2013a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1136\/ard-2024-226051_bib0027","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"key":"10.1136\/ard-2024-226051_bib0028","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1136\/ard-2024-226051_bib0029","doi-asserted-by":"crossref","first-page":"W193","DOI":"10.1093\/nar\/gkm226","article-title":"g:Profiler\u2013a web-based toolset for functional profiling of gene lists from large-scale experiments","volume":"35","author":"Reimand","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1136\/ard-2024-226051_bib0030","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2024-226051_bib0031","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinformatics"},{"key":"10.1136\/ard-2024-226051_bib0032","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/annrheumdis-2018-214379","article-title":"Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity","volume":"78","author":"Panousis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226051_bib0033","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: customizable protein\u2013protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1136\/ard-2024-226051_bib0034","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1136\/ard-2024-226051_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v028.i05","article-title":"Building predictive models in R using the caret package","volume":"28","author":"Kuhn","year":"2008","journal-title":"J Stat Softw"},{"key":"10.1136\/ard-2024-226051_bib0036","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/annrheumdis-2021-221835","article-title":"Serum interferon-\u03b1 levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity","volume":"81","author":"Chasset","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226051_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001257","article-title":"Urine and serum S100A8\/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment","volume":"6","author":"Davies","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-226051_bib0038","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/jid.2011.127","article-title":"CCL4L polymorphisms and CCL4\/CCL4L serum levels are associated with psoriasis severity","volume":"131","author":"Pedrosa","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard-2024-226051_bib0039","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/cr.2010.182","article-title":"NF-\u03baB signaling pathways regulated by CARMA family of scaffold proteins","volume":"21","author":"Blonska","year":"2011","journal-title":"Cell Res"},{"key":"10.1136\/ard-2024-226051_bib0040","doi-asserted-by":"crossref","first-page":"10546","DOI":"10.3390\/ijms231810546","article-title":"The Role of Matrix Metalloproteinase in Inflammation with a Focus on Infectious Diseases","volume":"23","author":"Lee","year":"2022","journal-title":"IJMS"},{"key":"10.1136\/ard-2024-226051_bib0041","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41436-020-01077-7","article-title":"Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19","volume":"23","author":"Vietzen","year":"2021","journal-title":"Genet Med"},{"key":"10.1136\/ard-2024-226051_bib0042","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12885-023-11768-4","article-title":"Cyclin B2 impairs the p53 signaling in nasopharyngeal carcinoma","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1136\/ard-2024-226051_bib0043","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/jcp.26816","article-title":"Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer","volume":"234","author":"Zhang","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1136\/ard-2024-226051_bib0044","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/25141","article-title":"Control of apoptosis and mitotic spindle checkpoint by survivin","volume":"396","author":"Li","year":"1998","journal-title":"Nat New Biol"},{"key":"10.1136\/ard-2024-226051_bib0045","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.biocel.2011.09.001","article-title":"Damage-specific DNA binding protein 1 (DDB1): a protein with a wide range of functions","volume":"43","author":"Iovine","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1136\/ard-2024-226051_bib0046","article-title":"Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study","volume":"13","author":"Nikoloudaki","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-226051_bib0047","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/acr.24901","article-title":"Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus","volume":"74","author":"Urowitz","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-226051_bib0048","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12920-018-0468-1","article-title":"Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus","volume":"12","author":"Petri","year":"2019","journal-title":"BMC Med Genomics"},{"key":"10.1136\/ard-2024-226051_bib0049","first-page":"1926","article-title":"Belimumab restores Treg\/Th17 balance in patients with refractory systemic lupus erythematosus","volume":"27","author":"Prete","year":"2018","journal-title":"Lupus (Los Angel)"},{"key":"10.1136\/ard-2024-226051_bib0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rdc.2019.07.001","article-title":"Treat to Target in Rheumatology: A Historical Account on Occasion of the 10th Anniversary","volume":"45","author":"Smolen","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard-2024-226051_bib0051","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226051_bib0052","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-226051_bib0053","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2020.01.018","article-title":"Treat-to-target in systemic lupus erythematosus: Where are we?","volume":"74","author":"R\u00edos-Garc\u00e9s","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1136\/ard-2024-226051_bib0054","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/acr.23867","article-title":"Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus","volume":"72","author":"Sharma","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-226051_bib0055","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/acr.24023","article-title":"Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus","volume":"72","author":"Yeo","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-226051_bib0056","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard-2023-224795","article-title":"Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort","volume":"83","author":"Parodis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226051_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.860726","article-title":"Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs","volume":"13","author":"Garantziotis","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-226051_bib0058","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-226051_bib0059","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2024-226051_bib0060","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.3390\/ijms22115842","article-title":"DNA Damage Response in the Adaptive Arm of the Immune System: Implications for Autoimmunity","volume":"22","author":"Manolakou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ard-2024-226051_bib0061","doi-asserted-by":"crossref","first-page":"eabo5840","DOI":"10.1126\/sciadv.abo5840","article-title":"ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus","volume":"8","author":"Manolakou","year":"2022","journal-title":"Sci Adv"},{"key":"10.1136\/ard-2024-226051_bib0062","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8214379","article-title":"DNA Damage and Deficiencies in the Mechanisms of Its Repair: Implications in the Pathogenesis of Systemic Lupus Erythematosus","volume":"2018","author":"Mireles-Canales","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1136\/ard-2024-226051_bib0063","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/15384101.2021.1912889","article-title":"The emerging relationship between metabolism and DNA repair","volume":"20","author":"Cucchi","year":"2021","journal-title":"Cell Cycle"},{"key":"10.1136\/ard-2024-226051_bib0064","article-title":"Mitochondrial impairment and repair in the pathogenesis of systemic lupus erythematosus","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-226051_bib0065","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrrheum.2013.147","article-title":"Oxidative stress in the pathology and treatment of systemic lupus erythematosus","volume":"9","author":"Perl","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-226051_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.806560","article-title":"The Role of Immunometabolism in the Pathogenesis of Systemic Lupus Erythematosus","volume":"12","author":"Robinson","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-226051_bib0067","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1172\/JCI200420345","article-title":"Altered lipid raft\u2013associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus","volume":"113","author":"Jury","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2024-226051_bib0068","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/art.22309","article-title":"Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus","volume":"56","author":"Flores-Borja","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-226051_bib0069","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148552","article-title":"Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies","volume":"132","author":"Robinson","year":"2022","journal-title":"J Clin Invest"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724477728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724477728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-226051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:33:24Z","timestamp":1762086804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724477728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0003496724477728"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-226051","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-226051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}